Affimed N.V. announced that Dr. Arndt Schottelius has notified the Company of his intention to resign as the Chief Scientific Officer of the Company effective as of the end of May 2024 and, during this period, he will support the search for his replacement. Dr. Schottelius plans to become the chief executive officer of a European biotech company. As part of the transition plan, the Company announced that the experienced financial and biotechnology industry executive Harry Welten will resign as a member of the Supervisory Board as of December 31, 2023 and will continue to operate in that capacity until a permanent successor has been appointed.

Mr. Welten has more than 20 years of U.S. and European executive management experience in the biotechnology, pharmaceutical and banking industries, and has served as CFO for several publicly traded biotechnology companies, including Kuros Biosciences AG (formerly Cytos Biotechnology AG), Horizon Pharma AG (formerly Nitec Pharma AG) and Arpida AG.